Deciphera, Allakos and Uniqure are all set for important data disclosures.
Dolutegravir’s patent expiry will pile on the pressure as Gilead and Merck get on the long-acting bandwagon.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
And Gilead has plans for its biannual injection in pre-exposure prophylaxis, too.
A decision is due on Bristol’s new leukaemia project, while Mallinckrodt and Mesoblast await their fates after mixed panel meetings.
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.